Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces its decision to initiate clinical developments of its lead myvacTM candidate, TG4050, and the finalization of its collaboration agreement with NEC.
March 5, 2019
· 5 min read